Thank you very much, Madam Chair.
Thank you for coming here today.
I have some questions, Mr. Ghalami. You stated that Bill C-11 was a very sound initiative. All of the witnesses who have testified so far have said that while the spirit of this bill is laudable, some of the details are problematic. For example, many scientists have voiced their concerns over the inclusion of risk group 2 pathogens in the bill. They also maintain that some of the concepts are too restrictive and that implementing some of the bill's measures could prove too costly for the laboratories.
You maintain that everything is fine for now, that your laboratories are safe and that you are doing everything you can to avoid any problems. My understanding of that statement is that the existing guidelines are adequate.